drugset / Trial / NCT05350852

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL

NCT05350852

Phase 1 Unknown 16 enrolled Zhejiang University
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with MRD+ B-ALL

Timeline

Start
2022-03-18
Primary completion
2024-03-30
Completion
2024-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ThisCART19A Cell therapy 5e+06 cells/kg
Subject ThisCART19A Cell therapy 8e+06 cells/kg
Subject ThisCART19A Cell therapy 1.2e+07 cells/kg

Indications

No indication recorded.